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Recently released data on cancer incidence in Japanese atomic bomb survivors are analyzed
using a variety of relative risk models that take account of errors in estimates of dose to assess
the dose response at low doses. If a relative risk model with a threshold (the dose response is
assumed linear above the threshold) is fitted to solid cancer data, a threshold of more than about
0.2 Sv is inconsistent with the data, whereas these data are consistent with there being no
threshold. Among solid cancer subtypes there is strong evidence for a possible dose threshold
only for nonmelanoma skin cancer. If a relative risk model with a threshold (the dose response is
assumed linear above the threshold) is fitted to the leukemia data, a threshold of more than about
0.3 Sv is inconsistent with the data. In contrast to the estimates for the threshold level for solid
cancer data, the best estimate for the threshold level in the leukemia data is significantly different
from zero even when allowance is made for a possible quadratic term in the dose response,
albeit at borderline levels of statistical significance (p=0.04). There is little evidence for curvature
in the leukemia dose response from 0.2 Sv upwards. However, possible underestimation of the
errors in the estimates of the dose threshold as a result of confounding and uncertainties
not taken into account in the analysis, together with the lack of biological plausibility of a
threshold, makes interpretation of this finding questionable. Environ Health Perspect
105(Suppl 6):1505-1509 (1997)
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Introduction
The shape ofthe dose-response curve for
cancer following ionizing radiation expo-
sure has profound implications for extrapo-
lation ofrisks at high doses and dose rates
to those at low doses and dose rates. It is
the possible risks arising from lowdose and
low dose-rate exposure to ionizing radia-
tion that are central to the setting ofstan-
dards for radiological protection. For
example, the International Commission on
Radiological Protection (ICRP) (1) recom-
mended a dose and dose-rate effectiveness
factor of2 on the basis ofanimal data, the
evidence for curvilinearity in the cancer
dose response in the bomb survivor data,
and other epidemiologic data. Although the
linear-quadratic dose response (with
upward curvature) found for leukemia is
perhaps the most often employed departure
from linearity in analyses ofthe shape of
the cancer dose-response curve in radia-
tion-exposed groups (2,3), other shapes are
possible for the dose-response curve (4).
For the dass ofdeterministic effects defined
by the ICRP (1), it is assumed that there is
a threshold dose below which there is no
effect. Such a form ofdose response has
also been used in analyses ofbrain damage
among those exposed in utero to the atomic
bombings in Hiroshima and Nagasaki,
Japan (5,6). The goal ofthis paper is to
examine the evidence foranypossible curvi-
linearity in the cancer dose-response curve
by fitting a variety ofrelative risk models
to recently released cancer incidence data
for Japanese atomic bomb survivors
(7,8); models allowing for a possible dose
threshold will be fitted, as well as models
incorporating quadratic terms in dose.
It is recognized that errors in the
estimates ofdose can substantially alter the
shape of the dose-response relationship
and hence the evidence for both a dose
response as well as any possible curvature
in that dose response. The problem ofran-
dom dosimetric errors for the Radiation
Effects Research Foundation (RERF) data
has been investigated by Jablon (9),
Gilbert (10), Pierce et al. (11), and Pierce
and Vaeth (3). Pierce and Vaeth (3) found
that after adjustment for dosimetric error
there were nonsignificant indications of
upward curvature in the solid cancer mor-
tality dose response, whereas the evidence
for curvilinearity became rather stronger
for leukemia mortality. Because of the
marked effect ofadjusting for dosimetric
errors on the shape ofthe dose-response
curve, all the analyses presented in this
paper will employ such dosimetric adjust-
ments, which use the methodology devel-
oped by Pierce et al. (11) applied to a
richer class of dose-response functions
than thelinear-quadratic models examined
byGilbert (10) and Pierce et al. (11).
Methods
The relative risk in the Japanese atomic
bomb survivor cancer incidence data in
stratum i with sex s, average age at expo-
sure (AAE) a, average time since exposure
(TSE) t, and true dose D, was assumed to
be given by:
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RR(i,D) =max[1+'{D>Dt} *{a, *(D-Dt)
+P, .(D
_D)2 }
.exp{o5*a+et},O]
This is a linear-quadratic relative risk
model with a hypothetical dose threshold
Dtwhere a, is the linear excess relative risk
(ERR) coefficient (Sv-1) in sex s, fi is the
quadratic ERR coefficient (Sv-2) in sex s;,
is the factor determining the log-linear
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adjustment to the ERR for AAE a (year-l);
E is the factor determining the log-linear
adjustment to the ERR for TSE t (year-1);
and where 1ID,D I is 1 ifD>D,and 0 oth-
erwise. In general, the true dose, D, is not
known; the only observable dosimetric
quantity in any stratum is the nominal (or
estimated) dose, d. Approximately unbi-
ased parameter estimates were obtained by
replacing RR(i,D) by avg[RR(i,D)ld] in the
model fitting, in which this last expression
represents the average of the relative risk
RR(i,D) over the stratum with average
nominal dose d. The true dose distribution
in each ofthe two cities was modeled by a
Weibull distribution in which the proba-
bility ofthe true dose being greater than D
is given by exp(-O-DO) and the distribu-
tion ofthe nominal dose, d, given the true
dose, D, is assumed to be log-normal with
median D. Jablon (9) investigated the
errors in the Japanese atomic bomb
dosimetry and found that the errors were
most likely to be log-normal, with a geo-
metric standard deviation (GSD) ofabout
30%. Following the example of Pierce et
al. (11) for various assumed values of the
GSD, the parameters ofthe Weibull models
were chosen to give approximately the
same distribution of nominal dose as seen
in the solid cancer (7) and leukemia and
lymphoma (8) incidence datasets. The fit-
ting ofthe Weibull distribution parameters
O and 0 was achieved by minimizing the
sum ofsquares ofthe differences between
observed and predicted cumulative distribu-
tions of the nominal dose at the average
dose within each nominal dose band. In
general, all models predicted a nominal
dose distribution that agreed well with that
observed. The analyses in this paper assume
35% GSD errors; it can be shown that
results are not sensitive to the precise choice
ofGSD in the range of0 to 45% (12).
Relative risk models were fitted to
Japanese atomic bomb survivor incidence
data by maximum likelihood (13), in
which it is assumed that the expected num-
ber of cases ofwhichever type cancer is
under consideration (various sorts of
leukemia or solid cancer) in stratum iwith
average nominal dose d(in Sv), is given by:
PYR2i *Ai *avg[RR(i,D) d]
where PYRid is the number ofperson-years
in stratum iwith average nominal dose d;
Xiis the base cancer rate in stratum i.
The solid cancer incidence data are
those used in the analysis ofThompson et
Table 1. Estimates of threshold value Dt in fit of linear threshold and linear-quadratic threshold models to cancer
incidence data.a
Linearthreshold Linear-quadratic threshold
Cancer site = Dt(Sv)(+95% Cl) = Dt(Sv (+95% Cl)
Solid cancers
Stomach 0.06 < 0.00, 0.27) 0.10 (<0.00, 0.31)
Colon 0.50 (0.09, >1.00) 0.64(<0.00, >1.00)
Liver 0.13 (<0.00, 0.71) 0.30 (0.08, 0.75)
Other digestive organs 0.36 (<0.00, >1.00) 0.04(<0.00, >1.00)
Lung <0.00 (<0.00, 0.25) <0.00 (<0.00, 0.35)
Nonmelanoma skin 0.45 (0.18, 0.75) 0.92 (0.53, >1.00)
Female breast 0.03 (<0.00, 0.14) 0.04(<0.00, 0.19)
Urinary 0.04(<0.00, 0.36) 0.03 (<0.00, 0.37)
Thyroid 0.04(<0.00, 0.19) 0.05 (<0.00, 0.29)
Other solid cancers <0.00 (<0.00, 0.90) <0.00 (<0.00, >1.00)
All solid cancers 0.04(<0.00, 0.16) 0.08 (<0.00, 0.23)
Leukemias
Acute lymphocytic leukemia 0.06 (<0.00, 0.18) 0.051<0.00, 0.18)
Acute myeloid leukemia 0.30 (0.08, 0.60) 0.32 (<0.00, 0.76)
Chronic myeloid leukemia 0.15(0.00, 0.28) 0.15 (<0.00, 0.30)
All leukemias 0.13 (0.04, 0.27) 0.12 (0.01, 0.28)
aShielded-kerma dose <4 Gy and (for solid cancers) colon dose <4 Sv or(for leukemias) bone-marrow dose <4 Sv;
35% dosimetric GSD assumed.
al. (7), whereas the leukemia incidence
data are those used in the analysis of
Preston et al. (8). The dose used for the
solid cancer data was that to the colon,
whereas the bone-marrow dose was used
for leukemia; in both cases a neutron rela-
tive biological effectiveness of 20 was
assumed, as recommended by the ICRP
(1). The a, are free to vary, withPf and D,
also free to vary as appropriate; D,was con-
strained to be nonnegative in all fits. The
AAE adjustment coefficient, 5, was allowed
to vary and the TSE adjustment coeffi-
cient, E, set to 0, for the model fits to the
solid cancer data; both the S and £ were
allowed to vary for the fits to the leukemia
data to allow for the known variations in
the data ofERR (or lack ofthem) with age
and time (7,8). Further details on the
methods used are found in a recent study
by Little and Muirhead (12).
Results
Table 1 and Figure 1 show that overall there
is little evidence for curvilinearity for the
solid cancer data. For example, if a linear
threshold model is fitted to the solid cancer
data, the value ofthe threshold dose below
which no elevation in risk is assumed is not
significantly greater than zero (best estimate
0.04 Sv, 95% CI<0.00, 0.16). Table 1 also
shows that in general there is no stronger
evidence of curvilinearity for particular
subtypes ofsolid cancer. Only for non-
melanoma skin cancer is there compelling
evidence for the presence ofa threshold. For
leukemia, there are stronger indications of
curvilinearity in the dose response. Table 1
shows that ifa linear model with a threshold
is fitted to the leukemia data, the value of
the threshold dose below which no eleva-
tion in risk is assumed is statistically signifi-
cantly greater than zero (p<0.01); the best
estimate is 0.13 Sv (95% CI 0.04, 0.27).
Surprisingly, much the same result
(p=0.04) is found when a linear-quadratic
threshold model is fitted (best estimate
0.12 Sv, 95% CI 0.01, 0.28). The improve-
ment in fit ofthe linear-quadratic threshold
model compared with that of the linear
threshold model is not statistically signifi-
cant (p=0.60). This last result shows that
the curvature in the leukemia dose response
takes place at low doses (<0.2 Sv), as Figure
1 also shows. Ifa linear threshold model is
fitted separately to each of the three
leukemia subtypes, only for acute myeloid
leukemia (AML) is there strong evidence
(p<0.01) for a dose threshold (best estimate
0.30 Sv, 95% CI 0.08, 0.60), perhaps
reflecting the fact that the largest number of
leukemia cases (102 of 190) are ofthis sub-
type. There also is evidence at borderline
levels ofstatistical significance (p=0.05) for
a dose threshold for chronic myeloid
leukemia. For the other main leukemia sub-
type (acute lymphocytic leukemia) the best
estimate of the threshold is positive,
although not significantly so. However, it is
clear from Table 1 that for each leukemia
subtype considered separately, the curvature
in the dose response is adequately described
byalinear-quadratic model.
Discussion
Analysis using a variety of models reveals
little evidence for curvilinearity for solid
cancers overall. In particular there is no
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Figure 1. Dose response for solid cancers and leukemia in A-bomb survivors (+95% Cl). Shielded-kerma dose
<4 Gy and (for solid cancers) colon dose <4 Sv or (for leukemia) bone-marrow dose <4 Sv). (A) all data; (B) low-
dose region ofA.
evidence for a dose threshold with fairly
tight upper bounds (= 0.2 Sv) on how large
a threshold there could possibly be. These
findings confirm the results of previous
analyses by the RERF of the dose response
for cancers other than leukemia in the Life
Span Study (LSS) cohort of the Japanese
atomic bomb survivors (2,7), which also
found little evidence for any curvature
in the dose response. The RERF analyses
considered a more restricted set of dose-
response models (generally only linear qua-
dratic) than that employed in this study
and, unlike the analyses described above,
did not consider random errors in dose esti-
mates (2,7). There is little evidence for
curvilinearity in the dose response for solid
cancers in any other group exposed to low
linear energy transfer (LET) radiation
(14,15). The dose response for solid cancer
following exposure to high LET radiation
also is generally linear (16,17), although
there is some evidence of nonlinearity in
the dose response for bone sarcomas in U.S.
women who workwith radium dials (18).
In contrast to the results found for solid
cancers, those in the analysis by the RERF
and other groups of the dose-response
curve for leukemia incidence and mortality
in the LSS cohort exhibited a marked qua-
dratic component, i.e., a significant upward
curvature (2,8). The evidence for nonlin-
earity in the incidence data is strongest for
AML (8). The fact that when both linear
threshold and linear-quadratic threshold
models are fitted to this data there is a barely
significant (p=0.04) threshold is also con-
sistent with a high degree ofcurvilinearity
in the dose response.
Although our analysis considers the
effects ofrandom errors in dose estimates, it
does not take into account possible system-
atic biases in the atomic bomb dosimetry.
Recently there have been indications of
inconsistencies between the most current
set of neutron dose estimates for the
Hiroshima bomb survivors (dosimetry sys-
tem 1986) and those measured by neutron
activation in mineral and metal samples
(19). It has been argued, however, that
these dosimetric uncertainties imply only
slight adjustments to the slopes of the
cancer dose-response curves in theJapanese
LSS cohort (20). Our analysis also does not
take into account the contribution ofnat-
ural background radiation and other non-
bomb sources of radiation e.g., medical
X-rays, although there is no reason to sup-
pose that the doses from these sources
would be different for survivors in different
atomic bomb dose groups (21,22). The
contribution to total dose (and therefore
also the contribution to uncertainties in
dose) made by radiation sources other than
atomic bombs would be relatively more
important at low (atomic bomb) doses
rather than at high doses.
It should be noted that given the
statistical uncertainties as well as the
impact ofpossible bias and confounding in
epidemiologic studies, a low-dose threshold
would be difficult to observe directly. For
these reasons this study's estimation of
thresholds in the dose response uses a
model-fitting approach to the Japanese
dataset, a cohort exposed to moderate
doses (average " 0.1 Sv) at a high dose rate.
The dangers of this modeling approach
must be recognized, namely that the evi-
dence for (or against) a threshold at low
doses may be partially driven by the pat-
terns ofrisk in the higher dose parts ofthe
Japanese incidence data.
Certain approximations are made in
this study. The analysis uses the average for
a given nominal dose, d, of the relative
risk RR(i,D) evaluated at true dose D:
avg[RR(i,D)Id]. The dataset used for
analyses ofboth leukemia and solid cancers
is in grouped form, with the strata defined
in each case by the variables for city, sex,
AAE, TSE, and dose. For each such stra-
tum, i, the average nominal dose over the
persons in that stratum (avgi[d]) is avail-
able. Ideally one should calculate for each
strataavgj[avg[RR(i,D)Id]], i.e., the average
of avg[RR(i,D)I.] over all individuals
in stratum i. It is impossible to calculate
this quantity using the grouped data pub-
licly available, so this analysis evaluates
avg[RR(i,D)lavgj[d]], i.e., the value of
avg[RR(i,D)I.] evaluated at the average
nominal dose (avgi[d]) within stratum i.
Even for linear dose-response models
there are potential differences between
avg[RR(i,D)Iavgj[d]] and avgi[avg[RR(i,D)I
d]]. Table 2 demonstrates that when
35% GSD dosimetric errors are assumed,
this approximation does not introduce
appreciable errors for the optimal linear
quadratic and linear-quadratic threshold
models for leukemia. Even for the smallest
values ofAAE and TSE, when the ERR is
largest and therefore when the proportional
errors in avg[RR(i,D)lavgi[d]] are the most
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Table 2. Errors in averaging hazard function for opti-
mal leukemia models.a
Percentage errorb
L[- L-Qthreshold
NDI,Sv M F M F
0.005-0.1 -0.47 -0.05 -4.20 -5.76
0.1-0.2 -0.33 -0.10 -3.62 -3.79
0.2-0.5 -1.12 -0.42 -0.51 0.37
0.5-1.0 -1.10 -0.49 -0.42 0.31
1.0-2.0 -1.48 -0.79 -0.66 0.44
2.0-3.0 -0.49 -0.28 -0.22 0.22
3.0-4.0 0.01 0.05 0.07 0.21
Abbreviations: F, females; L-Q, linear-quadratic; M,
males; NDI, nominal dose interval. 835% dosimetric
GSD assumed; AAE 0.5 years; TSE 7.5 years; averages
evaluated using 100 random samples from nominal
dose distribution. bh OO-{avg[RRi,D)Iavgj[d1]/
avgj[avg[RR(i,D)Idll-1 } (person-years) averaged
over city.
significant, errors are at most 5% for the
linear-quadratic threshold model; the
errors are somewhat less (generally < 1%)
for the linear-quadratic model (Table 2).
The magnitude of the relative error in
avg[RR(i,D)Iavgi[d]] from this source is
much the same for Hiroshima and
Nagasaki (results not shown). At least for
the linear-quadratic threshold model, in
the higher dose groups the relative error in
avg[RR(i,D)lavgi[d]] tends to be of equal
magnitude but of opposite sign for males
compared to that for females (Table 2).
It should be noted that the use of
threshold models is generally problematic,
since the asymptotic (x2) distribution ofthe
deviance difference statistic employed for
significance tests is not guaranteed because
oflack ofsufficient smoothness in the likeli-
hood function (23). However, this problem
is circumvented by the likelihood averaging
techniques used in this paper and in a com-
panion analysis (12) (at least when the dosi-
metric GSD is assumed to be non-zero).
The admittedly weak indications of a
possible threshold in the leukemia dose
response found in this analysis should be
considered in awider context. In particular,
the biological plausibility ofsuch a thresh-
old must be questioned. There is some evi-
dence from animal data for substantial
low-dose curvilinearity, and even possible
threshold effects, in the induction ofskin
cancer (24) and leukemia (25) in mice.
There are indications of beneficial or
hormetic effects ofvery low-dose irradiation
(0.004 Gy) in some large chromosomal
aberration studies (26), although there may
be problems with these data, the findings
from which have not been duplicated in
other studies (27). Cancers in general, and
leukemias in particular, are assumed to be
stochastic effects for which there generally
are no expectations of a dose threshold;
however, a threshold might be expected for
certain other categories of deterministic
effects such as sterility or cataract induction
(1). Because significant excess leukemia risk
has been observed in various occupationally
exposed groups (28) in which total doses
generally are administered in a hyperfrac-
tionated manner and also among those
exposed to small doses (< 20 mSv) ofX-
irradiation in utero (29), it is highly likely
that there is no threshold in the leukemia
dose response.
There is substantial evidence that
oncogenesis occurs because ofdamage to a
single cell and in particular because of
damage to genetic material (DNA) in the
cell nucleus that takes the form ofstable
gene or chromosome mutations (4). In the
case ofleukemia there is strong evidence
for the involvement ofspecific chromo-
some rearrangements in the neoplastic
process (30). For there to be an ionizing-
radiation dose threshold for leukemia, it
would be necessary to assume either a) that
single tracks of ionizing radiation cannot
induce the necessary damage in the target
tissue (cells in the bone marrow) or b) that
there is a totally efficient error-free system
ofrepair after damage from relatively small
doses of ionizing radiation. There is evi-
dence that single tracks ofall types ofion-
izing radiation can induce a variety of
damage including DNA double-strand
breaks (31,32), which are believed to be
critical lesions in radiation response. There
is also a body ofexperimental evidence that
argues against an error-free DNA repair
system operating at low doses of ionizing
radiation that might result in a dose
threshold for the induction of gene and
chromosomal mutations (27,33).
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